Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Analysis of the Dilated/ Hypertrophic Cardiomyopathy Space- with phase II Mavacamten data expected Q4

Ticker(s): MYOK

Who's the expert?

Name: Dr Roxana Ghashghaei - MD

Institution: UC Irvine

  • Cardiologist at UC Irvine with a focus on cardiomyopathies.
  • Currently treats 150 patients with Hypertrophic Cardiomyopathy. 
  • Published at the AHA and ISHLT with regards to advanced cardiomyopathies as well as mechanical circulatory support. 

Interview Questions
Q1.

Please tell us about your clinical practice, background in treating Obstructive/Nonobstructive Hypertrophic/Dilated Cardiomyopathy, and research in the space. How many patients do you treat,what is the first line of therapy? What % of patients do not respond well to first line?

Added By: slingshot_insights
Q2.

How much of a need for new treatments is still there? Which ones get prescribed often and under what specific circumstances?

Added By: slingshot_insights
Q3.

Do you emphasize treating the underlying cause, or do you focus more on alleviating symptoms? How often does the enlarged myocardium regenerate to its normal size following medication?

Added By: slingshot_insights
Q4.

What can you tell us about the recent P3 trial launch of mavacamten as an alternative to septal reduction therapy (SRT) ?

Added By: slingshot_insights
Q5.

What are the risks/ benefits associated with surgical myectomy or alcohol septal ablation procedures?

Added By: slingshot_insights
Q6.

What is Mavacamten’s mechanism of action leading to normalization of the number of myosin-actin cross-bridges?

Added By: slingshot_insights
Q7.

How important is the allosteric control of beta cardiac myosin? Was it possible prior to the development of Mavacamten?

Added By: slingshot_insights
Q8.

How important is the fact that mavacamten can be dosed to reduce left ventricular outflow tract (LVOT) gradient below the guideline-based definition for obstruction?

Added By: slingshot_insights
Q9.

In the PIONEER-OLE study, Mavacamten treatment resulted in reductions in patients’ resting and provoked LVOT gradient while maintaining a left ventricular ejection fraction (LVEF) above 55% at all times of assessment during the study through week 36. How do those nrs. translate to an improvement in the patients’ outcomes?

Added By: slingshot_insights
Q10.

How likely would you be to switch your patients to Mavacamten if approved?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.